Nexcella has announced FDA approval of IND application for a novel cell therapy, paving the way for its first US patient dosing.
The US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a new cell therapy drug. that aims (formerly HBI0101).
The drug, called BCMA CAR-T NXC-201, is developed by Nexcella, a clinical-stage biopharmaceutical company which develops novel cell therapies for oncology and other indications.
With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to the United States. Depending on its tolerability, there is the potential for expansion into autoimmune indications such as systemic lupus erythematosus (SLE), myasthenia gravis (MG) and multiple sclerosis (MS).
“Building on encouraging NXC-201 clinical data to date, we are thrilled that multiple leading U.S. sites are currently planning to enrol patients in the coming months,” said Ilya Rachman, MD PhD, executive chairman of Nexcella. “No approved treatment options currently exist for relapsed/refractory AL Amyloidosis patients.”
72 patients have been dosed – nine in AL Amyloidosis, 63 in multiple myeloma – with NXC-201. Relapsed/refractory AL Amyloidosis dose escalation levels demonstrated a 100 per cent overall response rate amongst the nine patients. For multiple myeloma, results demonstrated a 95 per cent overall response rate.
“We credit our world-class cell-therapy expert team in achieving this IND clearance in line with our previously communicated timelines,” said Gabriel Morris, president of Nexcella. “NXC-201’s favourable tolerability profile, including overcoming neurotoxicity, potentially enables expansion beyond AL Amyloidosis into autoimmune indications.”
Enhancing empathy and outcomes: The impact of digital design and UX for rare disease communities
Exploring success: Intelligent fieldwork and Fearsome in usability testing
Europe’s dedicated event for neuro rehabilitation experts returns
100th patient undergoes Deep Brain Stimulation at The London Clinic
Free app for people with Parkinson’s receives charity funding
Listen: Transforming the NHS skin cancer pathway
SurgTech 2024 will shine a light on innovation across the surgical pathway
Trusts to use AI to reduce skin cancer backlog and increase efficiency
Times are hard, but trusts can still make positive IT choices
AI helps cut nuisance alerts for healthcare teams
- News3 weeks ago
Data migration and interoperability specialist ReStart appoints Lynette Ousby as CEO
- Diagnostics1 week ago
Lenus puts automation at heart of diagnostic pathways with CDC Heart Failure roll-out
- Digital health3 weeks ago
UK an attractive market for digital innovators – report
- Insight7 days ago
Transforming NHS procurement: How good data holds the key to integrated care